What is an overview of rhabdomyosarcoma, including its diagnostic workup and management?

Rhabdomyosarcoma: Introduction, Diagnosis, and Management

Introduction

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, arising from skeletal myoblast-like cells and requiring aggressive multimodal treatment for cure. 1, 2 The disease occurs primarily in children, adolescents, and young adults, with distinct molecular subtypes that fundamentally determine prognosis and treatment approach 3.

Key Subtypes and Molecular Features

RMS is classified into distinct subtypes with different clinical behaviors:

• Embryonal RMS (ERMS): More favorable prognosis, typically occurs in younger children
• Alveolar RMS (ARMS): Associated with FOXO1-PAX3/7 gene fusions in 80-90% of cases, conferring significantly worse prognosis 3
• Spindle cell/sclerosing RMS: Intermediate prognosis
• Pleomorphic RMS: Typically occurs in older adults 4

The FOXO1-PAX3/7 fusion status is critical for risk stratification and should be identified through molecular testing, not just immunohistochemistry 5, 4. Contemporary trials report >80% survival in localized disease, but metastatic and relapsed RMS have 5-year overall survival below 30% 3.

Risk Factors

High-risk features for RMS include 3:

• Incompletely resected embryonal RMS at unfavorable sites
• Age ≥10 years
• Tumor size >5 cm
• Embryonal RMS with nodal involvement
• Alveolar RMS (with or without nodal involvement)

---

Diagnosis

Clinical Presentation

Look specifically for 6:

• Duration, intensity, and timing of pain (persistent non-mechanical pain is concerning)
• Swelling and functional impairment
• Primary site: Most commonly head/neck, genitourinary tract, and extremities 7
• Age at presentation: Diagnosis is strongly oriented by patient age

Histological Confirmation

Histological diagnosis must be established by incisional surgical biopsy or core needle biopsy, with identification of specific small round cell tumor types (including embryonal rhabdomyosarcoma) by immunohistochemistry AND cytogenetics 5.

• Core needle biopsy is preferred (multiple cores to maximize yield) 8, 9
• Image-guided biopsy (CT or ultrasound) should be performed by experienced centers
• Biopsy tract should be planned for removal during definitive surgery
• Molecular testing beyond immunohistochemistry is mandatory to identify fusion status 4

Staging Workup

Complete staging must include 5, 8:

1. Chest imaging: CT chest is mandatory to exclude pulmonary metastases (most common metastatic site)
2. Abdomen/pelvis CT: Especially important for RMS given metastatic patterns
3. Regional lymph node assessment: Critical for certain sites
   • Paratesticular RMS in patients >10 years old 10
   • Extremity RMS 10
   • Consider for synovial sarcoma, clear cell sarcoma, angiosarcoma, epithelioid sarcoma 8
4. PET-CT: Becoming standard in pediatric sarcomas including rhabdomyosarcoma 8, 7
5. Local imaging: MRI of primary site for surgical planning

Staging parameters include 5:

• Tumor size: ≤5 cm (T1) vs >5 cm (T2)
• Location: superficial vs deep
• Histological grade
• Extent of resection (Group assignment)

---

Management

Multidisciplinary Approach

All RMS patients must be managed at a reference center with a multidisciplinary sarcoma team 5, 6, 5. This is non-negotiable given the complexity and rarity of the disease.

Treatment Algorithm by Disease Stage

Localized Disease

The standard treatment consists of multimodal therapy: chemotherapy + surgery + radiation therapy 1, 2, 11.

Chemotherapy:

• Standard regimen: Vincristine + Actinomycin + Cyclophosphamide/Ifosfamide (VAC/VAI) 11, 12
• Preoperative chemotherapy is NOT standard for operable patients but can be considered with radiotherapy for borderline resectable tumors 5
• Adjuvant chemotherapy may be considered in younger patients with large, high-grade tumors 5

Surgery:

• Wide excision or compartmental resection including cutaneous scar and biopsy tract 5
• Maintain ≥0.5 cm resection margin 10
• Delayed primary resection after chemotherapy may increase complete resection rates with acceptable morbidity 12
• Re-operation is recommended for previous marginal or intralesional resection 5
• Mark tumor bed with surgical clips for radiation planning 10
• Regional lymph node evaluation required for paratesticular RMS (age >10) and extremity RMS 10

Radiation Therapy:

• After wide excision of high-grade sarcomas, adjuvant radiation therapy is recommended 5
• NOT necessary after radical surgery with compartmental excision or amputation at large distance from primary tumor 5
• Consider newer techniques: IMRT, proton beam, brachytherapy to reduce long-term sequelae 12, 13
• Preoperative radiation therapy suggested for unresectable tumors 10

Metastatic Disease

Chemotherapy is the standard treatment for metastatic disease 5:

• Doxorubicin with or without ifosfamide commonly used
• Consider resection of residual metastatic disease following chemotherapy 10
• Completely resectable lung metastases should be surgically resected 5

High-dose chemotherapy with autologous stem cell transplant (HDT/ASCT):

• There is NO proven survival benefit of HDT/ASCT in primary metastatic RMS 3
• Should NOT be used as standard therapy

Relapsed/Refractory Disease

• Resection of relapsed disease should be considered 10
• HDT/ASCT has NO proven survival benefit in relapsed RMS 3
• Second-line chemotherapy options include topotecan, carboplatin, or epirubicin 12
• Molecularly targeted agents under investigation 12

Non-Resectable Extremity Tumors

For non-resectable tumors confined to an extremity, chemotherapy with or without radiotherapy OR isolated hyperthermic limb perfusion offers an alternative to amputation 5.

---

Response Evaluation and Follow-Up

Response evaluation should be performed after 2-3 cycles of chemotherapy using the same radiological exams that were positive before treatment 5.

Follow-up schedule 5:

• Every 3 months: History and physical examination
• MRI of primary site: Twice yearly for first 2-3 years, then annually
• Chest X-ray (for high-grade tumors): Every 3-4 months for first 2-3 years, twice yearly up to year 5, then annually

---

Critical Pitfalls to Avoid

1. Do NOT rely on immunohistochemistry alone - molecular testing for fusion status is mandatory 4
2. Do NOT use HDT/ASCT for metastatic or relapsed RMS - no proven benefit 3
3. Do NOT skip regional lymph node evaluation in paratesticular RMS (age >10) or extremity RMS 10
4. Do NOT perform inadequate initial biopsy - ensure sufficient tissue for both histology and molecular testing 4
5. Do NOT manage outside specialized sarcoma centers - outcomes are significantly better with guideline-adherent treatment 9